How Will EMA’s Transparency Plans Impact on European Clinical Trials?
Everyone in Europe, it seems, is looking at transparency; it has become one of the dominant themes of the current debates over new clinical trial rules for the European Union. And for the clinical trial community, the European Medicines Agency’s (EMA) draft policy on the publication and access to clinical trial data is likely to be among the most crucial transparency developments for a long time ...Read more |
Pharm Exec Global Digest Market Access Special
In the new issue: Develop a Market Access Roadmap; Embed Market Access in Your Organizational Culture; Initiating Early Access Programs in Europe; and More! ... Read more
|
The Cancer Drug Fund under NHS England: First Quarter Results
NHSE has just released the first data covering the first quarter of financial year 2013/14 on the Cancer Drug Fund since they took it over. Leela Barham looks at what we can take away from it ... Read more
|
Making Social Media Sell
Pharma companies have been widely embracing social media to advertise products, recruit staff, and report on CSR projects. But it is it doing any good, asks Patrick Homer ... Read more
|
The Truth Behind the China Bribery Scandals
The last few weeks have seen the media swamped with stories about the rampant bribery clawing at the pharmaceutical industry in China. And many believe that it is just the tip of the iceberg, writes Adeline Siew ... Read more
|
| Products/Services Profiles |
|
| Sciformix |
 Product labeling– Increasing efficiency, enhancing quality, and delivering compliance
Pharmaceutical product labeling is a highly regulated and complex process. A product label is very specific in its content, with respect to safety data, adverse effects and compliance to country specific regulations.  Read More |
|
|
|
|
|
|
